Virtual Screening with Flexible Docking and COMBINE-Based Models. Application to a Series of Factor Xa Inhibitors

Journal of Medicinal Chemistry

Volumn 47, Issue 4, 2004, Pages 805-820

  Murcia, Marta ^a   Ortiz, Angel R ^a,b  

^a NEW YORK UNIVERSITY   (United States)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; DOCKING PROTEIN; LIGAND;

ALGORITHM; ANALYTIC METHOD; ARTICLE; CHEMOMETRIC ANALYSIS; LABORATORY DIAGNOSIS; LIGAND BINDING; PROTEIN CONFORMATION; SCREENING;

ALGORITHMS; FACTOR XA; LIGANDS; MODELS, MOLECULAR; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; REGRESSION ANALYSIS; SERINE PROTEINASE INHIBITORS;

EID: 0842304437     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030137a     Document Type: Article

References (72)

1. Matter, H.; Defossa, E.; Heinelt, U.; Blohm, P. M.; Schneider, D. et al. Design and quantitative structure-activity relationship of 3-amidinobenzyl-1H-indole-2-carboxamides as potent, non-chiral, and selective inhibitors of blood coagulation factor Xa. J. Med. Chem. 2002, 45, 2749-2769.
2. Rowland, R. S. Using X-ray crystallography in drug discovery. Curr. Opin. Drug Discovery Dev. 2002, 5, 613-619.
3. Neamati, N.; Barchi, J. J., Jr. New paradigms in drug design and discovery. Curr. Top Med. Chem. 2002, 2, 211-227.
4. Gohlke, H.; Klebe, G. Approaches to the description and prediction of the binding affinity of small-molecule ligands to macromolecular receptors. Angew Chem., Int. Ed. 2002, 41, 2644-2676.
5. Buchanan, S. G. Structural genomics: bridging functional genomics and structure-based drug design. Curr. Opin. Drug Discovery Dev. 2002, 5, 367-381.
6. Broder, S.; Venter, J. C. Sequencing the entire genomes of free-living organisms: the foundation of pharmacology in the new millennium. Annu. Rev. Pharmacol. Toxicol. 2000, 40, 97-132.
7. Agrafiotis, D. K.; Lobanov, V. S.; Salemme, F. R. Combinatorial informatics in the post-genomics ERA. Nat. Rev. Drug Discovery 2002, 1, 337-346.
8. Halperin, I.; Ma, B.; Wolfson, H.; Nussinov, R. Principles of docking: An overview of search algorithms and a guide to scoring functions. Proteins 2002, 47, 409-443.
9. Brooijmans, N.; Kuntz, I. D. Molecular Recognition and Docking Algorithms. Annu. Rev. Biophys. Biomol. Struct. 2003, 28, 28.
10. Schneider, G.; Bohm, H. J. Virtual screening and fast automated docking methods. Drug Discovery Today 2002, 7, 64-70.
11. Taylor, R. D.; Jewsbury, P. J.; Essex, J. W. A review of protein-small molecule docking methods. J. Comput. Aided. Mol. Des. 2002, 16, 151-166.
12. Ortiz, A. R.; Pisabarro, M. T.; Gago, F.; Wade, R. C. Prediction of drug binding affinities by comparative binding energy analysis. J. Med. Chem. 1995, 38, 2681-2691.
13. Wade, R. C. Derivation of QSARs using 3D structural models of protein-ligand complexes by COMBINE analysis. Rational Approaches to Drug Design: 13th European Symposium on Quantitative Structure-Activity Relationships; Prous Science S. A.: Barcelona, 2001; pp 23-28.
14. Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R.; Merz, K. M. et al. A Second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc. 1995, 117, 5179-5197.
15. Cuevas, C.; Pastor, M.; Perez, C.; Gago, F. Comparative binding energy (COMBINE) analysis of human neutrophil elastase inhibition by pyridone-containing trifluoromethyl ketones. Comb. Chem. High Throughput Screen 2001, 4, 627-642.
16. Ortiz, A. R.; Pastor, M.; Palomer, A.; Cruciani, G.; Gago, F.; et al. Reliability of comparative molecular field analysis models: effects of data scaling and variable selection using a set of human synovial fluid phospholipase A2 inhibitors. J. Med. Chem. 1997, 40, 1136-1148.
17. Pastor, M.; Perez, C.; Gago, F. Simulation of alternative binding modes in a structure-based QSAR study of HIV-1 protease inhibitors. J. Mol. Graph. Model. 1997, 15, 364-371, 389.
18. Perez, C.; Pastor, M.; Ortiz, A. R.; Gago, F. Comparative binding energy analysis of HIV-1 protease inhibitors: incorporation of solvent effects and validation as a powerful tool in receptor-based drug design. J. Med. Chem. 1998, 41, 836-852.
19. Wang, T.; Wade, R. C. Comparative binding energy (COMBINE) analysis of influenza neuraminidase-inhibitor complexes. J. Med. Chem. 2001, 44, 961-971.
20. Lozano, J. J.; Pastor, M.; Cruciani, G.; Gaedt, K.; Centeno, N. B. et al. 3D-QSAR methods on the basis of ligand-receptor complexes. Application of COMBINE and GRID/GOLPE methodologies to a series of CYP1A2 ligands. J. Comput. Aided Mol. Des. 2000, 14, 341-353.
21. Kmunicek, J.; Luengo, S.; Gago, F.; Ortiz, A. R.; Wade, R. C.; et al. Comparative binding energy analysis of the substrate specificity of haloalkane dehalogenase from Xanthobacter autotrophicus GJ10. Biochemistry 2001, 40, 8905-8917.
22. Tomic, S.; Kojic-Prodic, B. A quantitative model for predicting enzyme enantioselectivity: application to Burkholderia cepacia lipase and 3-(aryloxy)-1,2-propanediol derivatives. J. Mol. Graph. Model. 2002, 21, 241-252.
23. Tomic, S.; Nilsson, L.; Wade, R. C. Nuclear receptor-DNA binding specificity: A COMBINE and Free-Wilson QSAR analysis. J. Med. Chem. 2000, 43, 1780-1792.
24. Wang, T.; Wade, R. C. Comparative binding energy (COMBINE) analysis of OppA-peptide complexes to relate structure to binding thermodynamics. J. Med. Chem. 2002, 45, 4828-4837.
25. Leadley, R. J., Jr. Coagulation factor Xa inhibition: biological background and rationale. Curr. Top Med. Chem. 2001, 1, 151-159.
26. Porcari, A. R.; Chi, L.; Leadley, R. Recent advances in clinical trials of the direct and indirect selective Factor Xa inhibitors. Expert Opin. Investig. Drugs 2000, 9, 1595-1600.
27. Davie, E. W.; Fujikawa, K.; Kisiel, W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991, 30, 10363-10370.
28. Pauls, H. W.; Ewing, W. R. The design of competitive, small-molecule inhibitors of coagulation factor Xa. Curr. Top Med. Chem. 2001, 1, 83-100.
29. Quan, M. L.; Wexler, R. R. The design and synthesis of noncovalent factor Xa inhibitors. Curr. Top Med. Chem. 2001, 1, 137-149.
30. Wang, J.; Cieplak, P.; Kollman, P. A. How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules? J. Comput. Chem. 2000, 21, 1049-1074.
31. Perez, C.; Ortiz, A. R. Evaluation of docking functions for protein-ligand docking. J. Med. Chem. 2001, 44, 3768-3785.
32. Besler, B. H.; Merz, K. M.; Kollmann, P. A. Atomic charges derived from semiempirical methods. J. Comp. Chem. 1990, 11, 431-439.
33. Dewar, M. J. S. Z.; Eve G.; Healy, Eamonn F.; Stewart, James J. P. Development and use of quantum mechanical molecular models. 76. AMI: a new general purpose quantum mechanical molecular model. J. Am. Chem. Soc. 1985, 107, 3902-3909.
34. Stewart, J. J. MOPAC: a semiempirical molecular orbital program. J. Comput. Aided Mol. Des. 1990, 4, 1-105.
35. MOPAC 93; J. J. P. Stewart and Fujitsu Limited: Tokyo, Japan.
36. Bostrom, J. Reproducing the conformations of protein-bound ligands: a critical evaluation of several popular conformational searching tools. J. Comput. Aided Mol. Des. 2001, 15, 1137-1152.
37. Nelder, J. A.; Mead, R. A simplex method for function minimization. Computer J. 1965, 7, 308-313.
38. Bernstein, F. C.; Koetzle, T. F.; Williams, G. J.; Meyer, E. E.; Brice, M. D. et al. The Protein Data Bank: a computer-based archival file for macromolecular structures. J. Mol. Biol. 1977, 112, 535-542.
39. Case, D. A.; D. A. P.; Caldwell, J. W.; Cheatham, T. E., III; Wang, J.; Ross, W. S.; Simmerling, C.; Darden, T.; Merz, K. M.; Stanton, R. V.; Cheng, A. ; Vincent, J. J.; Crowley, M.; Tsui, V.; Gohlke, H.; Radmer, R.; Duan, Y.; Pitera, J.; Massova, I.; Seibel, G. L.; Singh, U. C.; Weiner, P.; Kollman, P. A. AMBER 7; University of California: San Francisco.
40. InsightII version 2000; Molecular Simulations, Inc.: San Diego, CA.
41. Sadowski, J.; Gasteiger, J.; Klebe, G. Comparison of Automatic Three-dimensional Model Builders Using 639 X-Ray Structures. J. Chem. Inf. Comput. Sci. 1994, 34, 1000-1008.
42. Sadowski, J.; Gasteiger, J. From Atoms and Bonds to Three-dimensional Atomic Coordinates: Automatic Model Builders. Chem. Rev. 1993, 93, 2567-2581.
43. Ortiz, A. R.; Strauss, C. E.; Olmea, O. MAMMOTH (matching molecular models obtained from theory): an automated method for model comparison. Protein Sci. 2002, 11, 2606-2621.
44. Wold, S.; Ruhe, A.; Wold, H.; Dunn, W. J., III. The collinearity problem in linear regression, the partial least squares (PLS) approach to generalized inverses. SIAM J. Sci. Stat. Comp. 1984, 5, 735-743.
45. Adler, M.; Davey, D. D.; Phillips, G. B.; Kim, S. H.; Jancarik, J.; et al. Preparation, characterization, and the crystal structure of the inhibitor ZK-807834 (CI-1031) complexed with factor Xa. Biochemistry 2000, 39, 12534-12542.
46. Maignan, S.; Guilloteau, J. P.; Pouzieux, S.; Choi-Sledeski, Y. M.; Becker, M. R.; et al. Crystal structures of human factor Xa complexed with potent inhibitors. J. Med. Chem. 2000, 43, 3226-3232.
47. Kamata, K.; Kawamoto, H.; Honma, T.; Iwama, T.; Kim, S. H. Structural basis for chemical inhibition of human blood coagulation factor Xa. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 6630-6635.
48. Baldi, P.; Brunak, S.; Chauvin, Y.; Andersen, C. A.; Nielsen, H. Assessing the accuracy of prediction algorithms for classification: an overview. Bioinformatics 2000, 16, 412-424.
49. Verkhivker, G. M.; Rejto, P. A.; Gehlhaar, D. K.; Freer, S. T. Exploring the energy landscapes of molecular recognition by a genetic algorithm: analysis of the requirements for robust docking of HIV-1 protease and FKBP-12 complexes. Proteins 1996, 25, 342-353.
50. Fradera, X.; De La Cruz, X.; Silva, C. H.; Gelpi, J. L.; Luque, F. J.; et al. Ligand-induced changes in the binding sites of proteins. Bioinformatics 2002, 18, 939-948.
51. Wong, C. F.; McCammon, J. A. Protein flexibility and computer-aided drug design. Annu. Rev. Pharmacol. Toxicol. 2003, 43, 31-45.
52. Carlson, H. A.; McCammon, J. A. Accommodating protein flexibility in computational drug design. Mol. Pharmacol. 2000, 57, 213-218.
53. Murray, C. W.; Baxter, C. A.; Frenkel, A. D. The sensitivity of the results of molecular docking to induced fit effects: application to thrombin, thermolysin and neuraminidase. J. Comput. Aided Mol. Des. 1999, 13, 547-562.
54. Birch, L.; Murray, C. W.; Hartshorn, M. J.; Tickle, I. J.; Verdonk, M. L. Sensitivity of molecular docking to induced fit effects in influenza virus neuraminidase. J. Comput. Aided Mol. Des. 2002, 16, 855-869.
55. Maignan, S.; Mikol, V. The use of 3D structural data in the design of specific factor Xa inhibitors. Curr. Top Med. Chem. 2001, 1, 161-174.
56. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
57. Kramer, B.; Rarey, M.; Lengauer, T. Evaluation of the FLEXX incremental construction algorithm for protein-ligand docking. Proteins 1999, 37, 228-241.
58. Gohlke, H.; Hendlich, M.; Klebe, G. Knowledge-based scoring function to predict protein-ligand interactions. J. Mol. Biol. 2000, 295, 337-356.
59. Jain, A. N. Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. J. Med. Chem. 2003, 46, 499-511.
60. Welch, W.; Ruppert, J.; Jain, A. N. Hammerhead: fast, fully automated docking of flexible ligands to protein binding sites. Chem. Biol. 1996, 3, 449-462.
61. Glick, M.; Grant, G. H.; Richards, W. G. Docking of flexible molecules using multiscale ligand representations. J. Med. Chem. 2002, 45, 4639-4646.
62. Wang, J.; Kollman, P. A.; Kuntz, I. D. Flexible ligand docking: a multistep strategy approach. Proteins 1999, 36, 1-19.
63. Maignan, S.; Guilloteau, J. P.; Choi-Sledeski, Y. M.; Becker, M. R.; Ewing, W. R. et al. Molecular structures of human factor xa complexed with ketopiperazine inhibitors: preference for a neutral group in the s1 pocket. J. Med. Chem. 2003, 46, 685-690.
64. Brandstetter, H.; Kuhne, A.; Bode, W.; Huber, R.; von der Saal, W. et al. X-ray structure of active site-inhibited clotting factor Xa. Implications for drug design and substrate recognition. J. Biol. Chem. 1996, 271, 29988-29992.
65. Guertin, K. R.; Gardner, C. J.; Klein, S. I.; Zulli, A. L.; Czekaj, M.; et al. Optimization of the beta-aminoester class of factor Xa inhibitors. Part 2: Identification of FXV673 as a potent and selective inhibitor with excellent In vivo anticoagulant activity. Bioorg. Med. Chem. Lett. 2002, 12, 1671-1674.
66. Arnaiz, D. O.; Zhao, Z.; Liang, A.; Trinh, L.; Witlow, M. et al. Design, synthesis, and in vitro biological activity of indole-based factor Xa inhibitors. Bioorg. Med. Chem. Lett. 2000, 10, 957-961.
67. Dudley, D. A.; Bunker, A. M.; Chi, L.; Cody, W. L.; Holland, D. R.; et al. Rational design, synthesis, and biological activity of benzoxazinones as novel factor Xa inhibitors. J. Med. Chem. 2000, 43, 4063-4070.
68. Wiley, M. R.; Weir, L. C.; Briggs, S.; Bryan, N. A.; Buben, J.; et al. Structure-based design of potent, amidine-derived inhibitors of factor Xa: evaluation of selectivity, anticoagulant activity, and antithrombotic activity. J. Med. Chem. 2000, 43, 883-899.
69. Pinto, D. J.; Orwat, M. J.; Wang, S.; Fevig, J. M.; Quan, M. L. et al. Discovery of 1-[3-(aminomethy])phenyl]-N-3-fluoro-2′ -(methylsulfonyl)-[1,1′-biphenyl]-4-yl]-3-(trifluoromethyl) -1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa. J. Med. Chem. 2001, 44, 566-578.
70. Nishida, H.; Miyazaki, Y.; Mukaihira, T.; Saitoh, F.; Fukui, M.; et al. Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as a factor Xa inhibitor II. Substituent effect on biological activities. Chem. Pharm. Bull. (Tokyo) 2002, 50, 1187-1194.
71. Ewing, W. R.; Becker, M. R.; Manetta, V. E.; Davis, R. S.; Pauls, H. W.; et al. Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa. J. Med. Chem. 1999, 42, 3557-3571.
72. Quan, M. L.; Ellis, C. D.; Liauw, A. Y.; Alexander, R. S.; Knabb, R. M.; et al. Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 2. J. Med. Chem. 1999, 42, 2760-2773.